Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells

Photodiagnosis and Photodynamic Therapy

Volumn 10, Issue 1, 2013, Pages 42-50

  Sun, Wei ^a,b   Kajimoto, Yoshinaga ^a   Inoue, Hiroto ^a   Miyatake, Shin Ichi ^a   Ishikawa, Toshihisa ^c   Kuroiwa, Toshihiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b SHANGHAI PUNAN HOSPITAL   (China)

^c RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

5 Aminolevulinic acid (5 ALA); ABCG2; Gefitinib; Photodynamic therapy (PDT); Protoporphyrin IX (PpIX)

Indexed keywords

AMINOLEVULINIC ACID; BREAST CANCER RESISTANCE PROTEIN; GEFITINIB; PROTOPORPHYRIN;

ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLIOMA; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84875398935     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2012.06.003     Document Type: Article

References (46)

1. Babilas P., Landthaler M., Szeimies R.M. Photodynamic therapy in dermatology. European Journal of Dermatology 2006, 16:340-348.
2. Huber R.M., Gamarra F., Hautmann H., et al. 5-aminolaevulinic acid (ALA) for the fluorescence detection of bronchial tumors. Diagnostic and Therapeutic Endoscopy 1999, 5:113-118.
3. Inoue K., Fukuhara H., Shimamoto T., et al. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer 2012, 118:1062-1074.
4. Hillemanns P., Weingandt H., Baumgartner R., Diebold J., Xiang W., Stepp H. Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence. Cancer 2000, 88:2275-2282.
5. Löning M., Diddens H., Küpker W., Diedrich K., Hüttmann G. Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer 2004, 100:1650-1656.
6. Zaak D., Sroka R., Khoder W., et al. Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid-first clinical experiences. Urology 2008, 72:345-348.
7. Kajimoto Y., Kuroiwa T., Miyatake S.I., et al. Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. Journal of Neurosurgery 2007, 106:1070-1074.
8. Stummer W., Novotny A., Stepp H., Goetz C., Bise K., Reulen H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. Journal of Neurosurgery 2000, 93:1003-1013.
9. Stummer W., Pichlmeier U., Meinel T., Wiestler O., Zanella F., Reulen H. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncology 2006, 7:392-401.
10. Miyatake S.I., Kuroiwa T., Kajimoto Y., Miyashita M., Tanaka H., Tsuji M. Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report. Neurosurgery 2007, 61:E1101-E1104.
11. Tamura Y., Kuroiwa T., Kajimoto Y., Miki Y., Miyatake S.I., Tsuji M. Endoscopic identification and biopsy sampling of an intraventricular malignant glioma using a 5-aminolevulinic acid-induced protoporphyrin IX fluorescence imaging system. Technical note. Journal of Neurosurgery 2007, 106:507-510.
12. Beck T.J., Kreth F.W., Beyer W., et al. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers in Surgery and Medicine 2007, 39:386-393.
13. Stummer W., Beck T., Beyer W., et al. Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. Journal of Neuro-Oncology 2008, 87:103-109.
14. Barnett A.a., Haller J.C., Cairnduff F., Lane G., Brown S.B., Roberts D.J.H. A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. International Journal of Cancer 2003, 103:829-832.
15. Cairnduff F., Stringer M., Hudson E., Ash D., Brown S. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. British Journal of Cancer 1994, 69:605-608.
16. Olzowy B., Hundt C.S., Stocker S., Bise K., Reulen H.J., Stummer W. Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid. Journal of Neurosurgery 2002, 97:970-976.
17. Angell-Petersen E., Spetalen S., Madsen S.J., et al. Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. Journal of Neurosurgery 2006, 104:109-117.
18. Mathews M.S., Angell-Petersen E., Sanchez R., et al. The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids. Lasers in Surgery and Medicine 2009, 41:578-584.
19. Anand S., Honari G., Hasan T., Elson P., Maytin E.V. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clinical Cancer Research 2009, 15:3333-3343.
20. Chua C., Zaiden N., Chong K.H., et al. Characterization of a side population of astrocytoma cells in response to temozolomide. Journal of Neurosurgery 2008, 109:856-866.
21. Robey R.W., Polgar O., Deeken J., To K.W., Bates S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer and Metastasis Reviews 2007, 26:39-57.
22. Tamura A., Onishi Y., Ran A., et al. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metabolism and Pharmacokinetics 2007, 22:428-440.
23. Jonker J.W., Buitelaar M., Wagenaar E., et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:15649-15654.
24. Krishnamurthy P., Ross D.D., Nakanishi T., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. Journal of Biological Chemistry 2004, 279:24218-24225.
25. An R., Hagiya Y., Tamura A., et al. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharmaceutical Research 2009, 26:449-458.
26. Saito H., Hirano H., Nakagawa H., et al. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. Journal of Pharmacology and Experimental Therapeutics 2006, 317:1114-1124.
27. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New England Journal of Medicine 2005, 353:2012-2024.
28. Inoue H., Kajimoto Y., Shibata M.A., et al. Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy. Journal of Neuro-Oncology 2007, 83:223-231.
29. Nakagawa H., Tamura A., Wakabayashi K., et al. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochemical Journal 2008, 411:623-631.
30. Lopez J.P., Wang-Rodriguez J., Chang C., et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Archives of Otolaryngology Head and Neck Surgery 2007, 133:1022-1027.
31. Madsen S.J., Angell-Petersen E., Spetalen S., Carper S.W., Ziegler S.A., Hirschberg H. Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers in Surgery and Medicine 2006, 38:540-548.
32. Peng Q., Warloe T., Moan J., et al. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Research 2001, 61:5824-5832.
33. Hofer S., Frei K., Rutz H.P. Gefitinib accumulation in glioblastoma tissue. Cancer Biology and Therapy 2006, 5:483-484.
34. Cusatis G., Gregorc V., Li J., et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute 2006, 98:1739-1742.
35. Rao V.K., Wangsa D., Robey R.W., et al. Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells. Cancer Genetics and Cytogenetics 2005, 160:126-133.
36. Jin Y., Bin Z.Q., Qiang H., et al. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. Journal of Cancer Research and Clinical Oncology 2009, 135:1369-1376.
37. Zhou S., Schuetz J.D., Bunting K.D., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine 2001, 7:1028-1034.
38. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nature Reviews Cancer 2005, 5:275-284.
39. Liu W., Baer M.R., Bowman M.J., et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clinical Cancer Research 2007, 13:2463-2470.
40. Raizer J.J. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. Journal of Neuro-Oncology 2005, 74:77-86.
41. Saito H., An R., Hirano H., Ishikawa T. Emerging new technology: QSAR analysis and MO calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, ABCG2 (BCRP). Drug Metabolism and Pharmacokinetics 2010, 25:72-83.
42. Adachi T., Nakagawa H., Chung I., et al. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. Journal of Experimental Therapeutics and Oncology 2007, 6:335-348.
43. Hagiya Y., Adachi T., Ogura S., et al. Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. Journal of Experimental Therapeutics and Oncology 2008, 7:153-167.
44. Ishikawa T., Nakagawa H., Hagiya Y., Nonoguchi N., Miyatake S., Kuroiwa T. Key role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis. Advances in Pharmacological Sciences 2010, 2010:587306.
45. Singh A., Wu H., Zhang P., Happel C., Ma J., Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Molecular Cancer Therapeutics 2010, 9:2365-2376.
46. Bleau A.-M., Huse J.T., Holland E.C. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009, 8:2936-2944.